MARC Record from Library of Congress

LEADER: 05433cam a22004334a 4500
001 2006018231
003 DLC
005 20070726084027.0
008 060602s2007 paua b 001 0 eng
010 $a 2006018231
016 7 $a101278142$2DNLM
020 $a0781793947
020 $a9780781793940
035 $a(OCoLC)ocm70051358
035 $a(OCoLC)70051358
040 $aDNLM/DLC$cDLC$dNLM$dBAKER$dC#P$dYDX$dBTCTA$dYDXCP$dVAM$dLVB$dNLGGC$dDLC
042 $apcc
050 00 $aRC924.5.L85$bL87 2007
060 00 $a2006 O-165
060 10 $aWR 152$bD8152 2007
082 00 $a616.7/72$222
084 $a44.83$2bcl
245 00 $aDubois' lupus erythematosus /$ceditors, Daniel J. Wallace, Bevra Hannahs Hahn.
246 30 $aLupus erythematosus
250 $a7th ed.
260 $aPhiladelphia :$bLippincott Williams & Wilkin,$cc2007.
300 $axvii, 1414 p. :$bill. (some col.) ;$c29 cm.
504 $aIncludes bibliographical references and index.
505 0 $aHistorical background of discoid and systemic lupus erythematosus -- The definition and classification of systemic lupus erythematosus -- Environmental aspects of lupus -- The epidemiology of systemic lupus erythematosus -- Overview of pathogenesis of systemic lupus erythematosus -- The genetics of human lupus -- The genetics of murine systemic lupus erythematosus -- Apoptosis -- The interaction of T cells with cells of the innate immune system and B cells in the pathogenesis of SLE -- Cytokines and interferons in lupus -- B cells in systemic lupus erythematosus -- Abnormalities in immune complex clearance and Fcy receptor function -- Complement and systemic lupus erythematosus -- Mechanisms of acute inflammation and vascular injury in systemic lupus erythematosus -- Idiotypes and idiotype networks -- The importance of sex hormones in systemic lupus erythematosus -- Neuroendocrine immune interactions: principles and relevance to systemic lupus erythematosus -- Animal models of systemic lupus erythematosus -- Pathogenesis of atherosclerosis in lupus -- Autoantigens and defects in immune tolerance in lupus -- The structure and derivation of antibodies and autoantibodies -- Antinuclear antibodies: an overview -- Antibodies to DNA -- Antibodies to histones and nucleosome-related antigens -- Antibodies to Ro/SSA and La/SSB -- Antibodies to spliceosomal components -- The lupus anticoagulant and antiphospholipid antibodies -- Other serologic abnormalities in systemic lupus erythematosus -- Pathomechanisms of cutaneous lupus erythematosus -- Lupus-specific skin disease (cutaneous LE) -- Lupus-nonspecific skin disease -- The clinical presentation of systemic lupus erythematosus -- The musculoskeletal system -- Cardiovascular manifestations of lupus -- Pulmonary manifestations of systemic lupus erythematosus --
505 0 $aClinical apsects of vasculitis and selected cutaneovascular manifestations of systemic lupus erythematosus -- The nervous system -- Psychopathology of lupus and neuroimaging -- Sjogren's syndrome -- Ocular, aural, and oral manifestations -- Hematologic and lymphoid abnormalities in systemic lupus erythematosus -- Gastrointestinal and hepatic manifestations -- Systemic lupus erythematosus in childhood and adolescence -- Drug-induced lupus -- Infections in systemic lupus erythematosus -- Serum and plasma protein abnormalities and other clinical laboratory determinations in systemic lupus erythematosus -- Clinical indices in the assessment of lupus -- Clinical application of serologic abnormalities in systemic lupus erythematosus -- Differential diagnosis and disease associations -- Mixed connective-tissue disease and overlap syndromes -- The mother in systemic lupus erythematosus -- The fetus in systemic lupus erythematosus -- Neonatal lupus -- Reproductive issues in women with autoimmune disease -- Lupus nephritis: pathology and pathogenesis -- Clinical and laboratory features of lupus nephritis -- Principles of therapy and local measures -- Nonsteroidals and salicylates for systemic lupus erythematosus -- Antimalarial therapies -- Systemic glucocorticoid therapy in systemic lupus erythematosus -- Immunosuppressive drug therapy -- Nonpharmacologic and complementary therapeutic modalities -- Fibromyalgia in SLE and the use of complementary and alternative medicine -- Hormones and gender-related issues -- Clinical and management aspects of the antiphospholipid antibody syndrome -- Additional therapies used in the management of lupus -- Adjunctive measures and issues: allergies, antibiotics, vaccines and disability -- Issues in drug development in SLE: clinical trial design, outcome, measures, and biomarkers -- Prognosis, mortality, and morbidity in systemic lupus erythematosus -- Biologics and stem cell therapies for lupus -- Appendics: A patient's guide to lupus erythematosus -- Lupus resource materials -- The medical outcome survey short-form general health survey.
650 0 $aSystemic lupus erythematosus.
650 0 $aLupus erythematosus.
650 12 $aLupus Erythematosus, Discoid.
650 12 $aLupus Erythematosus, Systemic.
700 1 $aWallace, Daniel J.$q(Daniel Jeffrey),$d1949-
700 1 $aHahn, Bevra.
700 1 $aDubois, Edmund L.$tLupus erythematosus.
856 41 $3Table of contents only$uhttp://www.loc.gov/catdir/toc/ecip0615/2006018231.html
856 42 $3Publisher description$uhttp://www.loc.gov/catdir/enhancements/fy0733/2006018231-d.html